# Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults

> **NCT02599896** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 49 (actual)

## Conditions studied

- Prevention of HIV Infection
- HIV Antibodies
- Monoclonal Antibody, Human
- Neutralizing Antibody

## Interventions

- **BIOLOGICAL:** VRC-HIVMAB080-00-AB (VRC01LS)
- **BIOLOGICAL:** VRC-HIVMAB060-00-AB (VRC01)

## Key facts

- **NCT ID:** NCT02599896
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-16
- **Primary completion:** 2018-07-25
- **Final completion:** 2018-07-25
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02599896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02599896, "Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02599896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*